Lytenava: England Becomes First to Fund Ophthalmic Bevacizumab For Wet AMD

 
• By Neena Brizmohun

Up to 40,000 people could be set to access Outlook Therapeutics’ Lytenava in England, according to health technology assessment institute NICE, which found the drug for wet age-related macular degeneration had similar health benefits to aflibercept and ranibizumab, and similar costs to aflibercept.

AMD Acronym Of Age-related Macular Degeneration - Eye
Lytenava has secured funding in England for treating wet AMD (Shutterstock)

More from Pink Sheet

More from Geography